Bryan Cave LLP named Washington partner Therese D. Pritchard as the next chairwoman, giving the firm its first woman head in its 140-year history and the first firm leader to come from an office outside St. Louis.
Pritchard, who is the head of the firm’s white collar, securities enforcement and litigation client service group, will take the helm in October after working alongside Don G. Lents, who has been firm chairman since 2004.
“Throughout her career, Terry has distinguished herself as both a skilled attorney and a remarkable leader,” Lents said in a statement.
Pritchard, who joined the firm in 1999, has concentrated her practice on securities and financial institutions enforcement and litigation, representing public companies, banks, accounting firms, broker-dealers, investment advisers, mutual funds, hedge funds and individuals under investigation, the firm said.
Prior to joining Bryan Cave, she was an Assistant Director of the Division of Enforcement of the Securities and Exchange Commission and Deputy Chief Counsel of the Office of Thrift Supervision.
During Lents’ chairmanship, Bryan Cave added 11 offices in the U.S., Europe and Asia and more than 300 lawyers. Between 2004 and 2014, firm-wide revenue grew by almost 63 percent from $384 million to $624 million, the firm said.
“We owe a great debt of gratitude to Don for his tireless commitment to Bryan Cave and his unwavering focus on client service, which will be a lasting legacy that will endure for many years to come,” Pritchard said.
Pritchard is the fourth woman to lead a firm ranked among the top 50 wealthiest by trade publication American Lawyer, the firm said. She joins the ranks of Kim Koopersmith, at Akin Gump Strauss Hauer & Feld LLP, longtime Goodwin Procter LLP chairwoman Regina Pisa and Jami Wintz McKeon, who was elected chairwoman of Morgan Lewis & Bockius LLP in October.
Bryan Cave has more than 1,100 lawyers and other professionals in over 30 offices across the U.S., Europe and Asia.
Wachtell, Kirkland on Harland Clarke Purchase of Valassis
Valassis Communications Inc. (VCI), the marketing company that distributes coupon packets and “Have You Seen Me?” missing-children notices, will be acquired by Harland Clarke Holdings Corp. in a deal valued at about $1.84 billion.
Wachtell, Lipton, Rosen & Katz provided legal advice to Harland Clarke. Cleary Gottlieb Steen & Hamilton LLP advised the company on the financing. Valassis’ legal adviser was Kirkland & Ellis LLP and McDermott Will & Emery LLP. Weil Gotshal & Manges LLP advised JPMorgan, adviser to the Valassis Board.
Wachtell Lipton’s team is led by corporate partners Adam O. Emmerich, Andrew J. Nussbaum and DongJu Song. Additional partners include: Nelson O. Fitts, antitrust; Adam J. Shapiro, executive compensation and benefits; Joshua A. Feltman, restructuring and finance; and Jodi J. Schwartz, tax.
Cleary’s lead partners include Laurent Alpert, David Lopez and Michael Volkovitsch.
The Kirkland team includes corporate partners Henry Kleeman and Richard Porter.
McDermott corporate partner Amy Leder led that firm’s team.
The Weil team includes New York partner Michael Aiello.
Valassis, based in Livonia, Michigan, offers a range of marketing services -- everything from direct-mail inserts to in-store coupon dispensers. Merging the businesses will create a marketing company that caters to the world’s biggest financial institutions, big-box retailers and government customers, said Chuck Dawson, chief executive officer of Harland Clarke.
For more, click here.
Capital Markets Partner to Join Milbank in Hong Kong
James Grandolfo joins Milbank, Tweed, Hadley & McCloy LLP as a partner in the Hong Kong office in the global securities group. He was previously at Allen & Overy LLP, where he was head of the Asia Pacific capital markets group.
Grandolfo has been based in Hong Kong since 2000, where his work includes advising underwriters, corporates, sovereign and quasi-sovereign issuers in the Philippines, India, Indonesia, Hong Kong, Pakistan, Malaysia, the PRC and Thailand. “As our capital markets practice in Asia continues to set the industry standard, we are very fortunate to gain the talents of James Grandolfo, who has developed a highly respected and successful practice in the region,”Milbank chairman Scott Edelman said in a statement.
Cozen O’Connor Adds New York Commercial Litigator Schlatner
Cozen O’Connor has added Adam J. Schlatner as a partner in its commercial litigation practice in New York. He was previously with Baker Hostetler LLP.
Schlatner has experience handling contract and partnership disputes, defending securities class and derivative litigation, and representing defendants in consumer fraud and antitrust class actions, as well as IP and employment matters, the firm said. He has represented the New York Stock Exchange, Inc., in the internal investigation and related litigation concerning the compensation of former NYSE Chairman and CEO Richard A. Grasso and has participated in the defense of several product liability and fraud actions against Philip Morris USA.
“At Cozen O’Connor, we have been actively strengthening our commercial litigation practice and our New York presence in order to better serve our clients,” Jeffrey G. Weil, chairman of Cozen O’Connor’s commercial litigation department and co-chairman of the firm’s litigation section said in a statement.
In October, Cozen O’Connor added five partners to its commercial litigation practice in New York from various firms.
Cozen O’Connor has 575 attorneys at 23 offices in the U.S. and Canada.
Health Care Partner Joins Foley’s Miami Office
Foley & Lardner LLP announced that Myla Reizen has joined the firm’s health care industry team as a partner in its Miami office. She previously led the health care industry team at Jones Walker LLP.
Reizen has experience covering health care government investigations and qui tam matters. She has also conducted internal investigations, and developed, implemented and evaluated compliance programs for health care providers, the firm said.
Foley & Lardner LLP has approximately 900 attorneys in 20 offices.
Pfizer’s Pick to Head New Drug Division to Leave Company
Pfizer Inc. (PFE)’s Amy Schulman, named to head one of the company’s three new drug units starting next month, will instead leave the company.
Schulman, a deputy to Chief Executive Officer Ian Read and Pfizer’s general counsel, was chosen in July to lead one of the businesses as the New York-based company reorganizes ahead of a potential breakup. Albert Bourla, a 20-year Pfizer veteran, will now head the unit, which handles vaccines, oncology and consumer health products, Pfizer said in a statement yesterday.
“Amy Schulman and Pfizer have agreed to separate,” the company said in a statement yesterday. She will stay at the company for a transition period, after a five-year tenure there. The company didn’t give a further reason for her departure or say she was leaving for another job.
Schulman joined Pfizer as general counsel in 2008. She was given leadership of the company’s nutrition unit in 2010, when it had $1.87 billion in sales. After that unit was sold, she headed the $3.12-billion-a-year consumer business, before being assigned the newly created drug unit.
“I have enjoyed my years at Pfizer and wish the company and my many friends and colleagues well,” Schulman said in an e-mailed statement provided by the company.
For more, click here.
To contact the reporter on this story: Elizabeth Amon in New York at firstname.lastname@example.org
To contact the editor responsible for this story: Michael Hytha at email@example.com